Spero Therapeutics, Inc.: Revision history

5 February 2023

• curprev 12:4012:40, 5 February 2023‎ 95.149.241.163 talk‎ 1,295 bytes −15‎ No edit summary undo Tag: Visual edit

20 August 2022

• curprev 19:2819:28, 20 August 2022‎ 95.149.241.133 talk‎ 1,310 bytes +11‎ No edit summary undo Tag: Visual edit: Switched

14 August 2022

• curprev 05:1705:17, 14 August 2022‎ 109.180.50.163 talk‎ 1,299 bytes +15‎ No edit summary undo Tag: Visual edit: Switched

9 August 2022

• curprev 07:3507:35, 9 August 2022‎ Paris talk contribs‎ 1,284 bytes +1,284‎ Created page with "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent t..." Tag: Visual edit